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The irritable bowel syndrome (IBS) is part of thelarger group of functional gastrointestinal (GI) dis-
orders that, despite differences in location and symptom
patterns, share common features with regard to their
motor and sensory physiology, central nervous system
(CNS) relationships, and the approach to patient care.1
IBS is a functional bowel disorder characterized by symp-
toms of abdominal pain or discomfort that is associated
with disturbed defecation.2 This disorder is highly prev-
alent and can be associated with significant emotional
distress, impaired health-related quality of life (HRQL),
disability, and high health care costs. Psychosocial fac-
tors, although not part of IBS per se, have an important
role in modulating the illness experience and its clinical
outcome.3
Knowledge of the pathophysiology of IBS and the
diagnosis and management of patients has previously
been hampered by few well-designed investigations, a
lack of diagnostic precision, and an absence of specific
treatments. In the last 5 years, since publication of the
previous AGA Technical Review on IBS,4 there has been
a notable increase in basic, mechanistic, and clinical
investigations that has improved our understanding of
this disorder and its physiological and psychosocial de-
terminants. The adoption of multinational symptom-
based criteria,1 particularly for clinical research studies,
has increased diagnostic precision, and within clinical prac-
tice, may lead to a reduction in unneeded diagnostic studies.
Finally, treatment methods have evolved toward use of
more integrated multicomponent pharmacological and be-
havioral strategies based on the severity of, and psychosocial
factors, influencing the patient’s symptom pattern.
This technical review updates our previous report.4
Based on a critical review and analysis of the existing
literature, we address: (1) the epidemiology and impact
of the disorder, (2) its pathophysiological determinants,
(3) the role of psychosocial factors in symptom experience
and behavior, (4) the diagnostic approach, and (5) rec-
ommendations for treatment.
Definition and Classification
The Rome classification system1 characterizes the
IBS in terms of multiple physiological determinants
contributing to a common set of symptoms rather than a
single disease entity. It is defined as a “group of func-
tional bowel disorders in which abdominal discomfort or
pain is associated with defecation or a change in bowel
habit, and with features of disordered defecation.”2,3




Table 2 gives the prevalence estimates for IBS
from population surveys among American, European,
and Australia/New Zealand adults. These prevalence es-
timates vary due to the diversity of definitional criteria
and to differences in the specific questions used to elicit
the information. There is also evidence that survey recall
rates for reporting bowel symptoms are frequently inac-
curate5 and are strongly influenced by anxiety.6
The data from Table 2 may be summarized as follows:
(1) the prevalence of IBS is greater in women; (2) the first
presentation of patients to a physician is between the
ages of 30 and 50 years, and there is a decrease in
reporting frequency among older subjects; and (3) the
prevalence seems to be similar in whites and blacks, but
may be lower in Hispanics. Sandler’s analysis of the
NHANES data27 shows a 5-fold greater prevalence of
IBS in whites than blacks. However, this was based on
self-report rather than symptom criteria or may have
been influenced by limited access to health care by
blacks. The overall prevalence was 2.9%. However, epi-
demiological studies of non-European American and
non-Western ethnic groups are limited and may be
confounded by cultural influences. Available studies sug-
gest that IBS seems to be as common in Japan, China,
South America, and the Indian subcontinent as it is in
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Western countries.3 There are limited data to address
incidence rates.
Symptom Features
In the short term (weeks to months), the symp-
toms of IBS occur frequently. In a study of 59 patients in
the United States, England, and the Netherlands, the
majority reported at least one GI symptom on over one
half of the days, and pain was reported one third of the
time.7 Symptom episodes (defined as a period of symp-
toms bounded by symptom-free days) occurred 12.4
times during the 12 weeks of observation and averaged 5
days/episode.
Over a longer period of time (years), the symptoms of
IBS wax and wane. When the prevalence of IBS is
examined in the same population at 2 time points sep-
arated by 12 months8 or 5 years,9 the point prevalence
remains almost unchanged. However, up to 40% of
subjects reporting symptoms at time 1 lose them at time
2, only to be replaced by new cases at time 2.
Health Care Utilization and the Health Care
Burden
In the United States, up to 70% of persons with
IBS symptoms do not seek medical attention.10,11 This
may relate to cultural factors,12 the presence and degree
of pain,13–17 and psychological disturbance.14,18 How-
ever, these rates are also influenced by access to health
care. In the United States, where up to 40% of patients
do not have easy access to health care, the consulting rate
is 46%,17 whereas in Australia, where health care access
is close to 100%, the consulting rate is 73%.19 IBS
accounts for 12% of patients seen in primary care prac-
tice and is the largest diagnostic group seen in GI
practice. Two surveys of AGA members20,21 undertaken
10 years apart show that functional GI disorders com-
prised respectively 41% and 35% of symptomatic out-
patients’ diagnoses, and IBS was the most frequent of the
functional GI diagnoses.
Patients with IBS, when compared with persons with
IBS not seeking health care or persons without bowel
symptoms, have more non-GI complaints and consult
physicians more for these symptoms.13,22,23 Female pa-
tients with IBS are 3 times as likely to receive a hyster-
ectomy24 and report more surgical procedures such as
appendectomies.25 In the U.S. Householder Study,17 per-
sons with IBS visited physicians 1.64 times in the year
before the survey for GI and 3.88 times for non-GI
complaints, compared with 0.09 and 1.77 times, respec-
tively, for persons without bowel symptoms.
Although most persons with IBS do not consult phy-
sicians, the cost to society in terms of direct medical
expenses and indirect costs, such as work absenteeism, is
considerable: (1) they miss 3 times as many work days as
those without bowel symptoms (13.4 days vs. 4.9 days)
and are more likely to report that they are too sick to
work (11.3 % vs. 4.2 %)17; (2) there are between 2.4 and
3.5 million physician visits annually for IBS in the
United States,26,27 during which 2.2 million prescrip-
tions are written27; and (3) they incur health care costs of
$4044 (1995 dollars), compared with $2719 for those
without IBS over the previous year.23 In a comprehensive
assessment of burden of illness for GI illnesses in the
United States, IBS was second only to esophageal reflux
disease in its prevalence (15.4 million people) and was
associated with $1.6 billion in direct and $19.2 billion in
indirect costs.28 By adding 3.5 million people suffering
from chronic diarrhea, the prevalence for lower func-
tional bowel disorders nears that of gastroesophageal
reflux disease.28 These data have important implications
with regard to the need to identify treatments that can
help improve HRQL and associated costs to society
among a very large clinical population.
Pathophysiology of IBS Symptoms
The physiological mechanisms responsible for ab-
dominal pain and altered bowel habits occur in healthy
control subjects and in persons with IBS. Symptoms can
occur in response to a disruption of functioning of the GI
tract from an infection, dietary indiscretions (e.g., in-
creased fat or alcohol intake), lifestyle changes (e.g.,
traveling or vigorous physical activity), or psychologic
stress. Among college students and hospital employees,
71% reported that stresses affected their bowel pattern,
Table 1. Rome II Diagnostic Criteria for Irritable Bowel
Syndrome3
At least 12 weeks, which need not be consecutive, in the
preceding 12 months of abdominal discomfort or pain that
has 2 of 3 features:
1. Relieved with defecation; and/or
2. Onset associated with a change in frequency of stool; and/or
3. Onset associated with a change in form (appearance) of
stool.
Symptoms that cumulatively support the diagnosis of IBS:
1. Abnormal stool frequency (for research purposes, “abnormal”
may be defined as greater than 3 bowel movements per day
and less than 3 bowel movements per week);
2. Abnormal stool form (lumpy/hard or loose/watery stool);
3. Abnormal stool passage (straining, urgency, or feeling of
incomplete evacuation);
4. Passage of mucus;
5. Bloating or feeling of abdominal distention.
NOTE. The diagnosis of a functional bowel disorder always presumes
the absence of a structural or biochemical explanation for the symp-
toms.
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and 54% reported that stress led to abdominal pain or
discomfort.10
Abnormal Motility in Patients With IBS
Table 3 details the studies of altered GI motility
in IBS and is summarized below. The differences be-
tween IBS patients and healthy controls are quantitative
rather than qualitative.
Motility observations in the stomach, small intestine,
colon, and rectum are qualitatively similar to those in
healthy controls. Moreover, only 25%–75% of IBS pa-
tients exhibit the motility “abnormalities” listed in Ta-
ble 3, which are considered to differentiate IBS from
healthy controls. These motility parameters cannot be
used as diagnostic markers.
In the ileum, colon, and rectum, IBS patients show an
exaggerated response to a variety of provocative stimuli
including meals, distention, stress, cholecystokinin,
neostigmine, and corticotropin-releasing hormone injec-
tion. No corresponding pattern of hyper-reactivity has
been shown in the proximal small intestine and stomach,
where the response to stress (inhibition of contractions)
differs from the response to meals (increase in contrac-
tions).
There is no consensus on the patterns of motility
responsible for diarrhea and constipation, although ac-
celerated transit is seen in diarrhea and slowed transit is
seen in constipation. Among IBS patients exhibiting
diarrhea and abdominal pain, there are significantly more
high-amplitude propagating contractions, which are of
higher amplitude than those observed in healthy con-
trols, and these high-amplitude propagating contractions
are more likely to be associated with a sensation of pain.
Motility abnormalities may interact with low sensory
thresholds to produce symptoms: delayed transit of gas
causes greater abdominal perception in IBS,29 and IBS
patients are more likely than healthy controls to perceive
the occurrence of normal migrating motor complexes.30
Visceral Hypersensitivity in IBS
In 1973, Ritchie first reported that IBS patients
have pain at lower volumes and pressures when a balloon
is inflated in the bowel.31 This seminal observation has
been replicated by a number of research laboratories,31–36
Table 2. Epidemiological Studies of IBS in Western Countries Using Symptom Criteria
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Osterberg et al.228 Stockholm 2707 (54) 31.5 (31.3–31.8) Rome I 10.6 13.3 7.4
Boyce et al.229 Sydney 2910 (72) 43.8 (43.2–44.3) Manning 13.6 17.2 9.8
Rome I 4.4 6.4 2.2
Rome II 6.9 9.2 4.6
Talley et al.230 Dunedin 890 (86) Longitudinal study
(ages 3–26)
2 Manning 12.7 14.6 10.8
Rome II 4.3 5.3 3.3
Thompson et al.231 Canada 1149 (57) Weighted age
sample (18 to
64)
Modif Rome II 12.1 15.2 8.7
Rome I 13.5 18.1 8.5
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and the threshold to report pain is below the normal
range in 50%–70% of IBS patients. Consistent with the
concept of enhanced perception of visceral events are
observations that IBS patients are more likely than con-
trols to notice intestinal contractions37 and gas,29 and
their pain thresholds are correlated, albeit weakly, with
the amount of clinical pain they experience.32,38,39
Enhanced perception of visceral events is documented
throughout the GI tract, including the esophagus,40 stom-
ach,41 duodenum,42–44 and ileum.45 However, IBS patients
do not show somatic hypersensitivity to pain42,46,47 and may
have elevated48,49 somatic pain thresholds.
One study32 noted that when combining other mea-
sures of pain sensitivity, such as the intensity with which
the pain sensation is described and the location and size
of the somatic referral area, up to 95% of patients show
evidence of visceral hypersensitivity. The investigators
concluded that visceral hypersensitivity might be a bio-
logical marker for IBS, although this interpretation has
been challenged.38
Inflammation
Preliminary evidence for a possible alteration in
gut immune function in IBS comes from both unselected
Table 3. Studies of Altered GI Motility in IBS
Motility Parameter Comments Study
Stomach
Delayed emptying, greater for solids Van Wijk et al.232; Evans et al.233; Caballero-
Plasencia et al.234
Anger inhibits antral motility Welgan et al.235
Electrogastrogram abnormal in 1/4 of IBS with comorbid





Increased frequency, duration of DCCs; DCCs associated
with pain
Kumar and Wingate237; Kellow et al.238; Schmidt
et al.239; Simren et al.240
No increase in DCCs Gorard et al.241
Increased DCCs following CRH Fukudo et al.242
Prolonged propagating
contractions
No increase in frequency, but PPCs associated with pain
in IBS
Kellow and Phillips243
Migrating motor complex Increased frequency of MMCs Kellow and Phillips45
Normal frequency of MMCs Gorard et al.241
Phasic contractions Duodenal and jejunal contractions suppressed by stress Kellow et al.244
Greater increase in ileum with distention, fatty meal and
CCK
Kellow and Phillips243
More retrograde duodenal and jejunal contractions Schmidt et al.239; Simren et al.240
Small bowel transit Delayed in IBS-C; accelerated in IBS-D Cann et al.245; Lu et al.246
Accelerated in IBS-D Vassallo et al.247
Impaired transit of infused gas resulting in discomfort/
pain
Serra et al.29
IBS patients more likely to perceive occurrence of MMCs Kellow et al.30
Colon and rectum
Phasic contractions No difference from control at rest, but greater increase
following rectosigmoid distention
Whitehead and Drescher248
Greater increase after meal Rogers et al.249
Greater increase with stress Welgan et al.111; Fukudo and Suzuki250
Greater increase with neostigmine Fukudo and Suzuki250
Increased number and amplitude of HAPCs in colon;
increased phasic motility in descending colon and
response to intravenous CKK
Ladabaum et al.251
Greater increase with CRH Fukudo et al.242
Myoelectric activity Increased long spike bursts with diarrhea; irregular short
spike bursts with constipation
Bueno et al.252
Compliance and tone Normal compliance in IBS Whitehead et al.248
Normal fasting and postprandial tone in descending
colon
Vassallo et al.253
Increased fasting muscle tone in rectum Whitehead et al.254; Blomhoff et al.255
Colonic transit Delayed in IBS-C; accelerated in IBS-D Cann et al.245
Whole gut and colonic transit accelerated in IBS-D, but
normal in IBS-C
Horikawa et al.256
DCC, discrete clustered contractions; CRH, corticotropin-releasing hormone; CCK, cholecystokinin; HAPC, high-amplitude propagated contrac-
tions; IBS-C, constipation predominant IBS; IBS-D, diarrhea-predominant IBS; MMC, migrating myoelectric complex; PPC, prolonged propagated
contractions.
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and so-called postinfectious IBS (PI-IBS) patients. In
unselected patients, increased numbers of mast cells in
the muscularis externa of the colon50 and the ileal and
colonic mucosa51,52 have been reported. Increased cellu-
larity of the colonic mucosa and lamina propria has also
been described in unselected IBS patients using semi-
quantitative microscopy.53 In patients with intractable
IBS, lymphocytic infiltrates of the myenteric plexus were
reported,54 and most recently, preliminary evidence for
increased iNOS (nitric oxide synthetase) expression was
described.55 For subgroups of IBS, these findings suggest
there is an up-regulation of gut immune function. How-
ever, methodological deficiencies exist, including the
influence of the bowel preparation, the classification of
the patients, and the nonquantitative analysis of gut
cells. Further studies are needed to explore these intrigu-
ing findings.
Further support for a possible role of altered gut
immune function in IBS comes from recent studies in
PI-IBS patients.56–59 A subset of IBS patients associate
the development of IBS symptoms with the onset of
gastroenteritis.60–62 In recent prospective studies,
IBS-like symptoms were found in 7%–30% of patients
who recovered from a proven bacterial gastroenteri-
tis.59 Reported risk factors included: female gender,
duration of the acute diarrheal illness, and the pres-
ence of significant life stressor occurring around the
time of the infection. Patients with PI-IBS were found
to have a variety of functional alterations, including
changes in gut motility,63,64 epithelial function,65,66
and an increase in colonic enterochromaffin cells.66 In
addition, evidence for increased expression of interleu-
kin 1 messenger RNA, increased cellularity of lam-
ina propria, and an increase in CD3 lymphocytes
were reported from mucosal biopsy specimens.66 The
correlation of IBS symptoms with these observed
changes has not been established. Furthermore, be-
cause the majority of patients do not develop postin-
fectious diarrhea and the prevalence of IBS is not
higher in countries with high rates of enteric infec-
tions, further studies are required to determine if
vulnerability factors (such as altered neuroimmune
system responsiveness) play a role in the development
of PI-IBS in a subset of patients. In addition, psycho-
logical distress seems to be an important cofactor in
determining who retains symptoms after an enteric
infection.67
Autonomic Activity
Abnormalities in extrinsic autonomic innervation
of the viscera occur in approximately one fourth of pa-
tients with functional bowel disorders.68,69 Aggarwal et
al. showed that cardiovagal dysfunction is specifically
associated with a constipation-predominant subgroup of
patients with IBS, whereas patients with diarrhea-pre-
dominant symptoms had evidence of sympathetic adren-
ergic dysfunction.70 The role of autonomic dysfunction
in IBS requires further evaluation.
Central Nervous System Modulation
In general, brain-gut interactions play a promi-
nent role in the modulation of gut function in health and
disease.71–74 Signals from the brain to the gut assure that
digestive function is optimized for the overall state of the
organism (e.g., sleep vs. wake, stress vs. relaxation).75
Conversely, signals from the gut to the brain play a role
primarily in reflex regulation76 as well as in modulation
of mood states.77 In addition, certain vagal afferent path-
ways can influence pain perception.78
The CNS modulates motility, secretion, immune
function, and blood flow.79 The emotional motor system
in the brain80 is a revised name for the limbic system and
some paralimbic structures (including the medial pre-
frontal cortex, amygdala, and hypothalamus) communi-
cate emotional changes via the autonomic nervous system
to the gut. The CNS is also essential in the perception of
events occurring within the gut. This brain-gut bidirec-
tional communication is largely not perceived con-
sciously. In effect, the CNS functions as a “filter” with
regard to the perception of peripheral afferent signals,
and the threshold for perception can vary depending on
the individual’s emotional and cognitive state. Most
visceral afferent signals reach the brainstem and thala-
mus, and only a very few are consciously perceived in the
cortex.81 However, one recent study82 suggests that low
intensity signals are subliminally registered.
Table 4. CNS Modulation of Gut Sensations
Central mechanism Targets of modulation Resulting mechanism of sensitization
Autonomic nervous system Gut effector cells (enterochromaffine cells, immune
cells, smooth muscle cells, ICCs)




Dorsal horn of spinal cord Central (spinal sensitization)
Ascending arousal systems83,89 Prefrontal and anterior cingulate cortex Hypervigilance
ICCs, interstitial cells of Cajal.
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Modulation of visceral afferent information occurs at
multiple levels from the periphery to cortical regions, as
shown in Table 4. The activation of these modulatory
systems is dependent on peripheral as well as central
events, even though the latter seem to be dominant. For
example, although acute gut inflammation results in
sensitization of peripheral, spinal, and central transmis-
sion,83 it is hypothesized that chronic inflammation may
adaptively down-regulate perceptual sensitivity.49,84,85
Stress, anxiety, or recall of aversive memories all can
enhance perception of painful events,86 whereas distrac-
tion, hypnosis, and relaxation can decrease perceptual
sensitivity.87,88 Stress-induced visceral hyperalgesia89
may be an important mediator of visceral hypersensitiv-
ity in IBS patients. Therapeutic approaches aimed at
attenuating stress responsiveness may effectively prevent
the development of stress-induced visceral hypersensitiv-
ity, as well as attenuate autonomic gut responses to
stress.90,91
Evidence for the alterations in the way the brain
responds to visceral stimuli, and how this response may
be altered in IBS patients, comes from recent studies
using functional brain imaging techniques.92–96 Two of
the studies, using distal colonic stimulation, have shown
a greater activation in IBS patients of the midcingulate
cortex, a brain region concerned with attentional pro-
cesses and response selection.97,98 Modulation of this
region by hypnotic suggestion was associated with
changes in the subjective unpleasantness of a somatic
pain stimulus in another study.88 The extent of abnormal
visceral afferent processing by the brain in IBS patients
needs to be established because they may be plausible
mediators of various therapeutic approaches: cognitive
therapies are likely mediated via networks involving the
lateral prefrontal cortex, which in turn enhance the re-
straining effect of the medial prefrontal cortex on the
emotional motor system.77 Hypnosis is likely to modu-
late attentional mechanisms (including the midcingulate
cortex),88,99 and relaxation exercises involving deep
breathing techniques may alter vagal afferent input to
the brain. Centrally targeted medications such as anxio-
lytics, low dose tricyclic antidepressants (TCAs), NK-1R
antagonists, and CRF1R (corticotropin releasing factor
1R) antagonists all involve inhibitory effects on the
responsiveness of the emotional motor system and pro-
vide options for future therapeutic investigations.
Role of Psychosocial Factors in IBS
Research on the psychosocial aspects of patients
with IBS has yielded 4 general observations.100
1. Psychologic stress exacerbates GI symptoms. Although
stressful experiences produce GI symptoms in most
individuals, patients with IBS are particularly sus-
ceptible.10 Studies of the effects of stressful life
events on IBS patients are shown in Table 5. With
one exception,101 these studies suggest IBS patients
report more lifetime and daily stressful
events,10,14,102–107 including severe abuse his-
tory,108,109 than medical comparison groups or
healthy controls. Furthermore, in IBS patients,
stress is strongly associated with symptom on-
set105,107,110 and symptom severity.109 Even though
the effects of stress on gut function are universal,
patients with IBS seem to have greater reactivity to
stress.72,111 The identification of specific psycholog-
ical stressors associated with exacerbation of symp-
toms may help in planning treatment through
psychological or psychopharmacological interven-
tions.
2. Psychological and psychiatric comorbidity is common
among patients with IBS. A large proportion of pa-
tients with IBS and other functional bowel disor-
ders have concurrent psychological disturbances.
As shown in Table 6, when using standardized
research interviews, the prevalence of a psychiatric
disorder ranges from 40% to over 90% among
patients with IBS/functional bowel disorders in
tertiary care centers. Other psychological features
identified to be greater in IBS include personality
style,14,106,112 psychological distress,18,109,113 and altered
health beliefs, cognitions, and coping style.114–117
As indicated below, these findings are not associ-
ated with the disorder per se, but their prevalence
is over-represented within the health care–seeking
subset of patients.
3. Psychosocial factors affect health status and clinical
outcome. Psychological and sociocultural factors,
when present in patients with IBS, will also influ-
ence the illness experience and treatment outcome.
Psychosocial factors that adversely affect health
status and clinical outcome include: (1) a history
of emotional, sexual, or physical abuse109,118–121;
(2) stressful life events104,110; (3) chronic social
stress122 or anxiety disorder123,124; and (4) maladap-
tive coping style.119 Some of these psychosocial
influences may occur early in life. For example,
increased attention by family to a child’s illness
complaints seems to result in delayed symptom
reporting, health care seeking, and health care
costs.125–129
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Table 5. Effects of Stress on IBS Symptoms
Subjects studied Assessment Results Study











135 IBS Self-report that stress
affects bowel symptoms
72.6% of IBS and 54.4% of controls reported stress led
to change in stool pattern
Drossman et al.10
654 Controls




Bedford College life events
and difficulties interview




72 IBS patients Standardized life event
scale
IBS patients reported: Drossman et al.14
82 IBS nonconsulters fewer negative stressful events and perceive them as
less severe84 Controls
fewer positive life events






on the life events and
difficulty schedule
60%–66% had experienced severe life events preceding
onset of IBS vs. 25% of controls for an arbitrary
time
Creed et al.110





Patients more likely to report physical or sexual abuse
compared with patients with organic GI disorders
Drossman et al.108
40 IBS Psychosocial assessment IBS patients: Dinan et al.106
32 Peptic ulcer reported greater negative life events
scored higher for neuroticism and extroversion






given every 3 months for
1 year (5 times)
Stressful events more common in IBS
Stress correlated with:
number of bowel symptoms
disability days
physician visits
Patients and nonpatients with IBS show greater
reactivity to stress than people without IBS
Whitehead et al.104







Abuse history was associated with poorer health status







Severe abuse history more prevalent in functional vs.
organic disorders
Drossman et al.109
26 IBS patients Evaluated relationship
between daily stress
using and GI symptoms
using daily diaries and
LES
IBS and IBS nonpatients vs. controls Levy et al.107
23 IBS nonpatients higher mean GI symptoms and stress
26 Controls no difference in LES scores
Within group both IBS and IBS nonpatients: significantly
positive relationship between daily stress and daily
symptoms
154 Children with RAP Consecutive daily telephone
interviews to assess daily
stressors and symptoms
More frequent daily stressors than well children Walker et al.105
109 Well children Association between daily stressors and symptoms was
stronger for patients with RAP than well children
LES, life event survey; RAP, recurrent abdominal pain.
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4. Psychosocial factors influence which patients consult phy-
sicians. This tends to overestimate the true preva-
lence of psychosocial disturbance when evaluating
patients in referral clinical settings. In fact, persons
with IBS who do not see physicians are psycholog-
ically similar to subjects without bowel com-
plaints.14,18,130
IBS Can Lead to Impaired HRQL
HRQL addresses the psychological and social con-
sequences of having IBS. It incorporates the patient’s
perceptions, illness experience, and functional status.131
Several self-administered questionnaires to study HRQL
now exist for GI disorders132 and IBS.133 To date, 2
IBS-specific instruments have been shown to be respon-
sive to change.134,135
The data show that patients with functional GI dis-
orders have poorer functional status (Sickness Impact
Profile) than those with organic GI diagnoses.109 In
addition, patients with IBS have significantly poorer
HRQL (SF-36) than the general population or of patients
with gastroesophageal reflux disease, and have selected
impairments in HRQL relative to patients with diabetes
and end-stage renal disease.136 However, the degree of
impairment also relates to the population being studied:
nonpatients with IBS have HRQL scores (SF-36) that are
intermediate between referred IBS patients (who were
similar to patients with congestive heart failure) and
normal controls.137 When using IBS-specific question-
naires, patients show the lowest scores related to inter-
ference with activity, food avoidance, and health worry
concern (IBS quality of life).138 Moreover, quality of life
improves in relation to changes in pain severity and daily
function after psychological or antidepressant treat-
ment.134 When compared with patients having other GI
conditions, physical, emotional, and social role functions
and energy (IBS quality of life) were poorer.139
Figure 1 provides a conceptual model on the role of
psychosocial factors on illness and outcome in IBS. Early
life factors influence later psychosocial experiences, phys-
iologic functioning, and susceptibility to developing
IBS. Therefore, a psychosocial stressor, interpreted from
previous experiences, may produce symptoms primarily
through changes in intestinal function, central amplifi-
cation of normal gut signals, or a combination of these
factors. The combined and integrated effects of altered
physiology and the person’s psychosocial status via the
brain-gut axis affects how the symptom is experienced,
the individual’s illness behavior, and ultimately the out-
come. Furthermore, the clinical outcome will, in turn,
affect the severity of the disorder. Therefore, while psy-
chosocial factors are not etiologic to IBS, they are rele-













32 (FBD) CIS 53% 20% — McDonald and Bouchier257
79 (FBD) PSE 42% 18% — Craig and Brown258
44 (IBS) PSE 42% 6% 8% Ford et al.101
37 (FBD) CIS 57% 6% — Colgan et al.259
48 (IBS) CIS 48% — — Corney and Stanton260
44 (IBS) DIS 61% — 14% Toner et al.261
68 (IBS) DIS 56% 25% 18% Blanchard et al.262
71 (IBS) DIS 94% 65% — Walker et al.263
50 (IBS) SCID 54% — — Irwin et al.264
FBD, functional bowel disorder (e.g., consecutive nonorganic gastrointestinal disorders in the clinic); CIS, clinical interview schedule; PSE,
present state examination; DIS, diagnostic interview schedule for diagnostic statistical manual (DSM-IIIR and DSM-IV); SCID, structured clinical
interview for DSM-IIIR and DSM-IV.
Figure 1. A conceptual model depicting the relationship between
early life, psychosocial factors, physiology, symptom experience, and
behavior and outcome. See text for details.
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vant to understanding the patient’s adjustment to IBS,
the clinical outcome, and the plan of treatment.
Diagnosis
Symptom-Based Criteria
A diagnosis is based on identifying positive symp-
toms (e.g., Rome criteria) consistent with the condition
(Table 1), and excluding, in a cost-effective manner,
other conditions with similar clinical presentations,
which may include organic or other functional (e.g.,
functional diarrhea or bloating, pelvic floor disorders, or
slow transit constipation with associated abdominal dis-
comfort relieved with defecation) disorders.3,140 Any
needed tests, as suggested by “alarm features,” should be
discussed with the patient and set up at the first encoun-
ter. When “alarm features” such as weight loss, refractory
diarrhea, and family history of colon cancer are excluded,
the specificity of the symptom-based Rome I criteria for
IBS exceeds 98% and hence, the risk of missing organic
disease is low.141
Evaluation
A physical examination should be performed on
the first visit and on subsequent visits as needed. This is
done to exclude findings not consistent with IBS (e.g.,
enlarged liver, abdominal mass, signs of bowel obstruc-
tion) and to meet the patient’s expectations of a thorough
evaluation. A pelvic examination is often indicated for
lower abdominal/pelvic symptoms and/or if there is a
change in menstrual pattern. A rectal examination, par-
ticularly for patients reporting symptoms of incontinence
or dyschezia, can help to identify a lax sphincter or
paradoxical pelvic floor muscle contraction. This may
require anorectal testing of pelvic floor muscle function.
Two algorithms applicable to the evaluation of pa-
tients with IBS seen in primary care settings have re-
cently been presented.142 Figures 2 and 3, as summarized
below, provide an algorithm for patients presenting to
gastroenterologists.
In general, if Rome criteria are fulfilled, “alarm signs”
or “red flags” are not present, and screening studies from
the referring physician are negative, further testing is not
needed. Screening studies are recommended when certain
historical information is present143: (1) short symptom
duration or worsening severity and trajectory of symp-
toms, (2) demographic features (e.g., onset in an older
patient), (3) family history (e.g., colon cancer or inflam-
matory bowel disease), and (4) no concurrent psychoso-
cial difficulties or symptom behaviors (particularly the
absence of comorbid psychosocial features or health care
seeking). We recommend a complete blood count and a
stool hemoccult for screening purposes. A sedimentation
rate (particularly in a younger patient), serum chemis-
tries, thyroid-stimulating hormone (TSH), and stool for
ova and parasites can be ordered based on symptom
pattern, geographic area, and relevant clinical features
(e.g., predominant diarrhea, areas of endemic infection).
However, studies do not generally support a role for
these tests without supportive clinical features.144 A
colonoscopy is recommended for patients over age 50
(due to higher pretest probability of colon cancer), but in
younger patients, performing a colonoscopy or sigmoid-
oscopy is determined by clinical features suggestive of
disease (e.g, if there is significant diarrhea) and may not
be indicated. There has been growing interest in the use
of antiendomysial (ema) and antigliadin (aga) antibodies
to diagnose celiac sprue.145–147 However, such testing
Figure 2. Initial evaluation by the gastroenterologist for patients with
IBS.
Figure 3. Diagnostic evaluation based on symptom subtype after
initial treatments are insufficient to control patient’s symptoms.
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must be put into a clinical perspective as determined by
presence of symptom pattern, ethnicity, and other clin-
ical features suggestive of the disease.143
In many cases, the therapeutic trial can be undertaken
before further diagnostic studies are done and will de-
pend on the symptom subtype and its severity (Figure 2):
for constipation, fiber, or an osmotic laxative; for diar-
rhea, loperamide, or diphenoxylate-atropine and possibly
cholestyramine; and for pain/gas/bloating, an anticholin-
ergic, or, if more severe, antidepressant or psychologic
treatment may be considered. It needs to be emphasized
that patients presenting with typical symptoms and no
“alarm” signs are rarely found to have another diagno-
sis,144,148 supporting the benefit of ongoing care and
symptomatic management rather than continued diag-
nostic evaluation.
If initial treatment fails, or certain clinical features
emerge requiring further evaluation, we recommend the
algorithm indicated in Figure 3. Many of these studies
are performed by gastroenterologists in specialty centers.
In patients with infrequent bowel movements, whole
gut transit study by Sitzmark technique or a plain radi-
ography (to evaluate for obstructive signs or fecal reten-
tion) is indicated. When symptoms of dyschezia or
incomplete evacuation are prominent, suggesting ob-
struction to defecation, or when the physical examination
discloses poor pelvic floor relaxation with straining, fur-
ther anorectal testing is indicated. This includes anorec-
tal motility testing with balloon expulsion (to evaluate
for pelvic floor dyssynergia) or defecography (to evaluate
for enterocele or rectocele).
If diarrhea is persistent, other tests to consider include:
24-hour stool volume and fat; if increased (400 mL/
day), electrolytes and laxative screen; and small bowel
biopsy for giardia lamblia or sprue and colonic biopsy for
microscopic colitis. On occasion, transit tests of the small
bowel and colon can help evaluate the severity of the
motility component of the diarrhea. A therapeutic trial
of cholestyramine may also be considered, particularly if
symptoms developed or worsened after a cholecystec-
tomy. A jejunal biopsy and aspirate can be done to obtain
samples to assess malabsorption (e.g., sprue), or to obtain
an aspirate for giardia or for bacterial overgrowth. Co-
lonic biopsies can be considered to evaluate for collage-
nous or lymphocytic colitis, although the findings may
not lead to instituting more effective treatments. Finally,
when postprandial symptoms of bloating and gaseous-
ness accompany the diarrhea, a breath H2 study to ex-
clude bacterial overgrowth can be considered.149
The persistence of pain-predominant symptoms or
severe bloating usually requires plain abdominal radiog-
raphy during an acute episode to exclude bowel obstruc-
tion, an increased gastric air bubble from aerophagia,
and/or other abdominal pathology. If negative, addi-
tional imaging studies (e.g., small bowel radiography,
computerized tomography scan, pelvic ultrasonography)
may be recommended, particularly when there are other
symptoms or signs present (e.g., vomiting, weight loss,
abdominal mass, irregular menses, abnormal chemis-
tries). A balloon distention test may confirm rectal or
colonic visceral hypersensitivity, although this test is
usually done for investigative purposes.
Treatment
The treatment strategy is based on the nature and
severity of the symptoms, the correlation of IBS symp-
toms with food intake and/or defecation, the degree of
functional impairment, and the presence of psychosocial
difficulties and psychiatric comorbidity affecting the
course of the illness. Table 7 provides a practical frame-
work, supported by recent empiric evidence150 for dif-
ferentiating patients into subgroups of severity based
primarily on patient pain reports and behaviors.22,151,152
In general, milder symptoms relate primarily to visceral
hyperactivity and/or hypersensitivity and are commonly
treated symptomatically with pharmacological agents di-
rected at the gut, whereas more severe symptoms are
associated with greater levels of psychosocial difficulties
and illness behaviors and often require psychological/
behavioral and antidepressant medications.
The most frequently seen group of IBS patients have
mild symptoms. They are usually cared for in primary
care practices, usually maintain normal daily activities,
have little or no psychosocial difficulties (although they
may experience symptom exacerbations with stress), and
are not high health care users. Treatment involves edu-
cation, reassurance, and dietary/lifestyle changes. A
smaller proportion of patients have moderate symptoms
Table 7. Spectrum of Clinical Features Among Patients
With IBS
Clinical feature Mild Moderate Severe
Estimated prevalence 70% 25% 5%
Practice type Primary Specialty Referral
Correlation with gut
physiology   
Symptoms constant 0  
Psychosocial difficulties 0  
Health care use   
Illness behavior 0  
Psychiatric diagnoses 0  
0, Generally absent; , mild; , moderate; , marked. Data
from Drossman.265
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that are usually intermittent, although at times dis-
abling. Symptoms may be associated with considerable
symptom-related distress, and historical symptoms are
associated with greater physiological gut reactivity (e.g.,
worse with eating, relieved by defecation). Treatments
involve gut-acting pharmacological agents (e.g., anticho-
linergics, antidiarrheals, newer GI treatments, etc.), and
if more persistent, possibly low-dose TCAs and/or psy-
chological treatments. Finally, only a very small propor-
tion of patients with IBS have severe and sometimes
refractory symptoms. These symptoms predominate
among patients seen in referral centers; these patients
frequently have more severe, often constant pain symp-
toms, psychiatric comorbidity (e.g., depression, anxiety
disorders), and psychosocial difficulties (history of sexual/
physical abuse, poor coping) associated with high health
care use rates. These patients require antidepressant med-
ication and possibly mental health or pain center referral,
along with an ongoing relationship with the primary care
physician to provide psychosocial support through brief,
regular visits.153
General Treatment Approach
The therapeutic relationship. An effective physi-
cian-patient relationship is the cornerstone of effective
treatment. Here, the physician must: (1) listen actively
to determine the patient’s understanding of the illness
and his or her concerns, (2) provide a thorough explana-
tion of the disorder, (3) identify and respond to the
patient’s concerns and expectations, (4) set realistic and
consistent limits, (5) involve the patient in the treat-
ment, and (6) establish a long-term relationship with a
primary care provider.153,154 This type of approach is
associated with a reduction in health care visits155 and
improved patient satisfaction. Patients who do not feel
properly informed have more health care visits.156 Fur-
thermore, when diagnostic and prognostic information is
provided, there is also a reduction in symptoms.157
As with any chronic illness, it helps to determine the
immediate reasons for the patient’s visit. These may
include: (1) everyday environmental stressors (e.g., diffi-
culty meeting deadlines, financial or relationship prob-
lems, daily “hassles”), (2) new exacerbating factors (e.g.,
dietary change, concurrent medical disorder, side effects
of new medication), (3) personal concern about a serious
disease (e.g., recent family death), (4) psychiatric comor-
bidity (e.g., depression, anxiety), (5) major life events or
difficulty adjusting to them (e.g., family death, abuse
history), (6) impairment in daily function (e.g., recent
inability to work or socialize) or (7) a “hidden agenda”
(e.g., narcotic or laxative abuse, pending disability or
litigation).
Education and reassurance. Education involves
an iterative process in which the physician assesses the
patient’s level of knowledge about the disorder and pro-
vides information, verbally or in print, to enhance the
patient’s understanding. Patients frequently want to un-
derstand the basis for their symptoms, and, at times, seek
validation that their symptoms are “real.” In practice,
useful statements include: “You have a common disorder
where the intestine overreacts to a variety of stimuli such
as food, hormonal changes, medication, and stress. These
stimuli can produce spasm or stretching of the gut,
enhanced sensitivity of nerves, or both. This is experi-
enced as pain, diarrhea, constipation, bloating, or any
combination anywhere in the abdomen.” or “IBS is a
disorder where communication between the brain and
gut is not in order, so bowel disturbance may trigger
symptoms of anxiety or distress, which in turn, makes
your symptoms worse. We need to understand both your
physical symptoms and the associated emotional distress
related to it.”
Reassurance should follow after the physician elicits
the patient’s worries and concerns, and after an adequate
and generally conservative diagnostic evaluation. If reas-
surance is communicated in a perfunctory manner before
evaluation, the patient will reject it.
Dietary modification. Although many patients
may attribute their symptoms to specific food substances,
the type of food does not generally contribute to symp-
toms. Patients are more likely to experience symptoms as
a generalized effect of eating, and at times may even
become conditioned to reduce eating to avoid postpran-
dial discomfort. However, certain dietary substances may
aggravate symptoms in some individuals. This might
include fatty foods, beans, and gas-producing foods, al-
cohol, caffeine, lactose in lactose-deficient individuals,
and, in some cases, excess fiber. Care should be taken to
avoid an unnecessarily restrictive diet.
Although fiber has an established role in treating
constipation, its value for IBS for the relief of diarrhea is
controversial and not helpful for pain. In 2 randomized
crossover studies of IBS patients,158,159 the groups receiv-
ing increased fiber (15 g bran and 20 g corn fiber,
respectively) and the control groups had similar degrees
of symptomatic improvement.
Symptom monitoring. It helps to have the pa-
tient use a diary to monitor symptoms for 2–3 weeks to
assess the time and severity of symptoms, the presence of
possible aggravating factors, and the emotional and cog-
nitive impact of the symptoms on the individual.153,160
The diary may identify dietary indiscretions or specific
stressors not previously considered, and may also give the
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patient a sense of participation in the planning of care.
The physician can then review and consider diet, life-
style, or behavioral modifications with the patient. In
addition, identification of maladaptive coping styles
(e.g., “catastrophizing”)119 may lead to referral for psy-
chological treatment.
Pharmacotherapy Targeted at Specific
Symptoms
For pain and bloating, antispasmodic (anticholin-
ergic) medication, particularly when symptoms are exacer-
bated by meals, should be considered. Meta-analyses of
available studies suggest that some of these agents may be
effective, although the trial methodology was inadequate by
modern standards.161 In one meta-analysis of smooth mus-
cle relaxants in IBS,162 5 drugs showed efficacy over placebo:
(1) cimetropium bromide (an antimuscarinic compound),
(2) pinaverium bromide and (3) octylonium bromide (qua-
ternary ammonium derivatives with calcium-antagonist
properties), (4) trimebutine (a peripheral opiate antagonist),
and (5) mebeverine (a derivative of beta-phenyl-ethylamine
that has antimuscarinic cholinergic activity). None of these
drugs underwent extensive trials in North America or re-
ceived approval from the Food and Drug Administration
(FDA). Notably, the commonly prescribed dicyclomine and
hyosyamine were not effective in the meta-analysis. Other
meta-analyses have been published with similar conclu-
sions.163–165 Eight trials with peppermint oil for IBS, in-
cluding a meta-analysis of 5 placebo-controlled, double-
blind trials, have not established a role for this treatment in
IBS.166 There are also meta-analyses on the effect of tricyclic
antidepressants, which will be reviewed later.
In clinical practice, antispasmodics and anticholin-
ergic agents are best used on an as-needed basis up to 3
times per day for acute attacks of pain or before meals
when postprandial symptoms are present. Agents such as
dicyclomine or mebeverine seem to retain efficacy when
used on an as-needed basis, but become less effective
with chronic use. Low-dose TCAs may be considered
when the pain is more constant and/or disabling.
For constipation, increased dietary fiber (25 g/day) is
recommended for simple constipation, although its ef-
fectiveness, based on several studies, in reducing pain in
constipation-predominant IBS is mixed (see dietary mod-
ification section). If fiber is not helpful, osmotic laxatives
such as milk of magnesia, sorbitol, or polyethylene glycol
may be used. For diarrhea, loperamide (2–4 mg up to 4
times daily) or diphenoxylate (2.5 mg and .025 mg
atropine up to 3–4 times a day) can reduce loose stools,
urgency, and fecal soiling,167 and in low doses, does not
seem to affect the CNS. Cholestyramine may be consid-
ered for a subgroup of patients with cholecystectomy or
bile acid malabsorption.65
Investigational Compounds
A novel approach to the treatment of diarrhea and
pain/discomfort of IBS is based on antagonism of the
5-HT3 receptors. 5-HT3 receptors are extensively distrib-
uted on enteric motor neurons, on peripheral terminals of
visceral afferent nerves, and on central locations such as
the vomiting center. Antagonism of these receptors re-
duces visceral pain, colonic transit, and small intestinal
secretion.168 Alosetron hydrochloride, a selective 5-HT3
antagonist, is effective in relieving pain and normalizing
bowel frequency, and reducing urgency in diarrhea-pre-
dominant female patients with IBS (effect size 12%–
15%).169 It was more effective than placebo in inducing
adequate relief of pain and discomfort and improved
bowel frequency, consistency, and urgency170–172 in
women with diarrhea-predominant IBS. The most com-
mon adverse event was constipation, affecting 28% of
patients in clinical trials; only 10% withdrew from these
studies for this symptom. A significant adverse event
with an unclear relationship to alosetron is acute isch-
emic colitis, estimated to occur in 0.1%–1% (risk factors
were not identified). The drug was withdrawn from the
market in November 2000 because of these side effects,
but after further evaluation was reapproved by the FDA
in the spring of 2002 under restrictive guidelines to be
developed for its use.
Another 5-HT3 antagonist, cilansetron, has demon-
strated similar efficacy to that of alosetron in 2 phase II
trials173 and was effective in male patients (possibly
because of a larger number of male patients studied).
This drug is currently in phase III trials.
For constipation, new partial or full 5-HT4 agonists
seem promising in the treatment of constipation or con-
stipation-predominant IBS. The partial agonist, tegas-
erod, is an aminoguanidine indole, which was shown to
result in global relief of IBS symptoms and constipation
in females with constipation-predominant IBS.174 The
effective dose of tegaserod is 12 mg per day in 2 divided
doses (6 mg twice daily). Pooled analysis of the trials to
date suggests that the drug is significantly effective, with
approximately a 10% advantage over placebo in the
intent to treat population and up to a 14% advantage
over placebo in females and those with documented
constipation during the baseline run-in period. Tegas-
erod appears safe, with no serious adverse events reported
in the clinical trials program or in open evaluation for
over 6 months. An effect of tegaserod on the delayed
rectifier potassium current that rarely leads to cardiac
dysrhythmias has been carefully excluded; this appears to
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differentiate the drug from other 5-HT4 agonists such as
the substituted benzamide, cisapride. The drug was ap-
proved by the FDA in July 2002 for females with con-
stipation-predominant IBS symptoms.
The full 5-HT4 agonist, prucalopride, is a benzofuran
that induces strong contractions in the proximal colon in
vivo in dogs175 and accelerates colonic transit in healthy
participants176,177 and in patients with functional consti-
pation.74 The drug induced a significant increase in the
number of spontaneous and complete bowel movements
in 2 trials of patients with functional constipation.178,179
The effects of prucalopride on abdominal pain have not
been thoroughly assessed. Clinical trials have been dis-
continued because of carcinogenicity in animals.
Other new approaches being explored in phase II studies
include: newer type 3 antimuscarinic agents, NK1 and
NK3 receptor antagonists, cholecystokinin antagonists, the
alpha2 adrenergic agonists, clonidine,180 a 5-HT1 agonist
(buspirone),181 and a selective serotonin reuptake inhibitor
(SSRI) (citalopram).182,183 Recommendations on the use of
these newer receptor-active agents with regard to being
first- or second-line treatments need to be determined based
on issues of efficacy, safety, and cost.
Complementary/Alternative Therapies
in IBS
Several reports indicate that the public holds
some skepticism toward conventional medicine and are
using complementary or alternative medicine therapies
more frequently in IBS than with “organic” diseases.184–187
However, the efficacy of alternative therapies has not
been established in controlled trials.188 One exception is
a placebo-controlled 16-week trial of Chinese herbal
medicines that showed improved bowel symptom scores,
global symptoms, and reduced IBS-related interference
with life relative to placebo.189 Notably, patients receiv-
ing individualized Chinese herbal medicine continued to
report benefit beyond the actual treatment period.189
Many herbs were used, so it is not possible to make
specific recommendations.
Psychological Treatment
Psychological treatment can be considered when
IBS symptoms are moderate to severe, when patients
have failed to respond to medical treatments, or when
there is evidence that stress or psychological factors are
contributing to GI symptom exacerbations. The patient’s
understanding of the rationale for psychological treat-
ment and their motivation to undertake such treatment
is critical to a successful outcome. Therefore, the physi-
cian has an important role in clearly communicating why
referral for psychological treatment is recommended. If
this is not done properly, patients may not accept the
referral and may even feel abandoned by their physicians.
Table 8 indicates that psychological treatments are fre-
quently helpful both at reducing bowel symptoms and
improving psychological symptoms.
Psychological treatment trials have methodological
limitations because of the inability to blind patients or
the investigators as to treatment assignment, and the
difficulty of coming up with a placebo treatment that is
credible, but also not effective, to patients. There are 14
randomized controlled trials (Table 8), but only 5 in-
cluded placebo arms; 2 of these placebo-controlled trials
were positive,190–192 1 showed a trend for greater bowel
symptom reduction in the active treatment group,193 and
2 showed equivalence between active and placebo
arms.194–195 Many trials have compared the active psy-
chological intervention to continuation of standard med-
ical therapy or merely to symptom monitoring while
waiting to start therapy. However, it is probable that
both these control groups are associated with a negative
expectancy. Patients are only referred to these trials if
they have failed medical therapy, and they are not ex-
pected to improve while they are waiting to be treated.
Thus, despite a number of positive trials, there is room
for doubt.
Currently, no studies indicate that one psychological
intervention technique is superior to another. The symp-
toms associated with a favorable response are abdominal
pain, diarrhea, and psychological distress.196 Predictors of a
positive response to psychological treatment124,196 are: (1)
awareness that stress exacerbates their bowel symptoms, (2)
at least mild anxiety or depression, (3) the predominant
bowel symptom is abdominal pain or diarrhea and not
constipation, (4) the abdominal pain waxes and wanes (rath-
er than being constant) in response to eating, defecation, or
stress, and (5) the symptoms are of relatively short duration.
Also, it has been proposed that patients who exhibit mal-
adaptive coping styles or cognitions (e.g., “catastrophizing”)
relating to their symptoms, or perceive an inability to
decrease them, may be particularly responsive to cognitive-
behavioral treatment.119,197
Psychological treatment is initially expensive because
it requires multiple, long sessions. However, its benefits
persist or even increase over time,196 and in the long run
there may be a net reduction in clinic visits and health




Antidepressants and anxiolytic agents are com-
monly prescribed by medical physicians, whereas anti-
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psychotics and mood stabilizers (for which there is little
evidence for benefit in IBS) may be prescribed by psy-
chiatrists consulting on patients with IBS.
Antidepressants. Several antidepressants are pre-
scribed in IBS: TCAs (e.g., amitriptyline, desipramine,
imipramine, doxepin), SSRIs (e.g., fluoxetine, sertraline,
paroxetine, citalopram), or less frequently, novel antide-
pressants (e.g., venlaxafine, mirtazapine). The rationale
includes: (1) treatment of psychiatric comorbidity (e.g.,
major depression, anxiety disorders usually using full
therapeutic doses) associated with IBS,199–201 (2) alter-
ation of GI physiology (e.g., visceral sensitivity, motility,
and secretion),202–206 or (3) reduction of central pain
perception arising from afferent signals in the gut.207–209
There is also some evidence that antidepressants may be
synergistic with psychological treatment for medical210
and psychiatric211 disorders. They may improve the mo-
tivation for psychologic treatments, which may increase
compliance with the medication. Although full antide-
pressant doses of TCAs are used less frequently today for
the treatment of psychiatric conditions (mainly because
of their high side effect rates), they are commonly pre-
scribed in smaller doses for the treatment of a variety of
chronic pain conditions and functional disorders, includ-
ing IBS.212
Several randomized controlled trials of TCA medica-
tions in IBS have been published100 and were evaluated
in a meta-analysis.212 Improvement in global GI symp-
toms against placebo was highly significant (odds ratio,
4.2; 95% confidence interval, 2.3–7.9), and there was
also improvement in standardized pain scores by 0.9 SD
(95% confidence interval, 0.6–1.2). Furthermore, only
Table 8. Randomized Controlled Studies of Psychological Treatments With at Least 20 Subjects and Follow-up at
Least 3 Months
N Type of treatment Comments Study
Interpersonal psychotherapy
n  101 Psychodynamic therapy vs. SMT Greater improvement in pain and bowel habits at
EOT and 15 mo FU
Svedlund et al.266
n  102 Interpersonal therapy vs. SMT Greater improvement in pain, bowel habits,
psychological symptoms at EOT and 12 mo FU
Guthrie et al.196
n  257 Interpersonal therapy vs. SSRI
vs. SMT
No differences in psychological status or bowel
symptoms at EOT or 12 mo FU
Creed et al.267
Cognitive behavior therapy
n  24 Multicomponent behavior therapy
vs. SMT
Greater reductions in psychological, but no
difference in bowel symptoms
Bennett and Wilkinson268
n  45 Summary of 5 small-scale
studies of a multicomponent
self-regulatory treatment
58% had primary GI symptoms reduced by at least
50%; trait anxiety had noticeable clinical utility
as an individual predictor of outcome
Blanchard et al.124
n  120 Multicomponent behavior therapy
vs. placebo vs. SMT
No difference between active treatment and
placebo; both superior to SMT
Blanchard et al.194
n  20 Individual CBT vs. SMT Reduced bowel symptoms at EOT and 3 mo FU Greene and Blanchard269
n  34 Individual CBT vs. self-help
support group vs. SMT
Bowel symptoms and psychological symptoms
reduced relative to placebo at EOT and 3 mo FU
Payne and Blanchard190
n  45 Group CBT vs. SMT Decreased bowel symptoms and increased ability
to cope at EOT and 2 year FU
Van Dulmen et al.270
n  101 Group CBT vs. education vs. SMT CBT showed greater reductions in psychological
distress and tended to show greater reduction
in bowel symptoms
Toner et al.193
n  24 Multicomponent behavior therapy
vs. SMT
Reduced bowel and psychological symptoms at
EOT and 6 mo FU
Heymann-Mönnikes et al.271
n  95 CBT vs. relaxation vs. SMT All groups equivalent Boyce et al.195
Hypnosis
n  30 Individual hypnosis vs. placebo
pill  supportive
psychotherapy
Greater improvement in bowel symptoms and well-
being at EOT and 18 mo FU
Whorwell et al.191,192
Relaxation/stress management
n  20 Relaxation by autogenic training
vs. SMT
Decreased pain and medical clinic visits at EOT
and 40 mo FU
Voirol and Hipolito272
n  35 Relaxation and stress
management vs. SMT
Improved bowel symptoms at EOT and 12 mo FU Shaw et al.273
EOT, end of treatment; FU, follow-up; SMT, standard medical treatment; CBT, cognitive behavior therapy.
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3.2 patients needed to be treated to improve symptoms
in 1 patient. In general, even though a wide range of
doses were used in these studies, TCA dosages were lower
than that used to treat major depression, suggesting that
the therapeutic effect was largely unrelated to the TCA’s
antidepressant effects. The study limitations (e.g., small
sample sizes, short study lengths, variable study design
quality, use of outcome measures and medication dos-
ages, large losses to follow-up, failure to assess effective-
ness of blinding, whether the benefits relate to improve-
ment in comorbid psychiatric disorders) indicate that
better-designed studies are needed to determine the
mechanism of benefit and the subpopulations most ame-
nable to treatment.
Table 9 compares the TCAs and provides prescribing
recommendations. In general, TCAs have more estab-
lished benefit over SSRIs. Because antidepressants are
used on a continual, rather than an “as needed” basis,
they are usually prescribed for patients having chronic or
frequently recurring symptoms. Low doses of TCAs (e.g.,
10–50 mg/day) are recommended for treatment of pain
and sleep difficulties associated with IBS, presumably
because of their multiple receptor blocking effects (anti-
cholinergic, antihistaminergic, antiadrenergic) in addi-
tion to their nonselective monoamine uptake inhibition
(serotonin, noradrenaline).213 Low doses of TCAs also
lead to a more rapid onset of action than full doses used
for treating major depression. They are also inexpensive
and do not carry the potentially serious cardiovascular
side effects associated with full antidepressant doses.
However, there is some evidence203 that full dosages of
TCAs may also provide benefits when lower dosages are
not effective. Notable side effects to the use of high-dose
TCAs include sedation, hypotension, and constipation,
among others (particularly for amitriptyline, doxepin,
and imipramine, over desipramine or nortriptyline), and
there is a greater need for dosage adjustments and a
greater risk for overdose. If used in higher doses, physi-
cians should be aware of these risks and monitor their
patient expectantly.
There are no published controlled studies on the use of
SSRIs or novel antidepressants for IBS. However, studies
of patients with other painful medical conditions suggest
clinical benefits even in the absence of depression,214,215
and these agents may have an advantage over TCAs for
treating other comorbid psychiatric disorders (e.g., ob-
sessive-compulsive disorder, anxiety disorders, and pho-
bias). Furthermore, physiological studies suggest that
they accelerate intestinal transit,206 although the thera-
peutic value of such peripheral effects remains to be
determined.
SSRIs are often prescribed particularly for older pa-
tients because of their lower side effect profile. They also
are superior in treating associated emotional symptoms
of anxiety, panic, obsessional behaviors, and constipa-
tion-predominant IBS. Specific agents may be consid-
ered: fluoxetine has a long half life and may be selected
when poor compliance is an issue, citalopram has a low
side effect profile and may prove beneficial because of
peripheral effects on colonic tone and sensitivity in
Table 9. Comparison of Tricyclic and SSRI Antidepressants
Low-dose TCA SSRI High-dose TCA
Compounds (dose range) Amitriptyline (10–50 mg) Fluoxetine (10–20 mg) Desipramine (100–200 mg)
Imipramine (10–50 mg) Sertraline (25–100 mg) Nortriptyline (100–200 mg)
Doxepin (10–50 mg) Paroxetine (20–40 mg)
Desipramine (10–50 mg) Citalopram (20–40 mg)
Nortriptyline (10–50 mg)
Potential benefits Pain, sleep disturbance Depression, panic, anxiety, OCD Pain, depression, anxiety
Time to onset of
therapeutic effect











Weight gain Weight loss Weight gain
Rare sexual dysfunction Sexual dysfunction Sexual dysfunction
Risk from overdose Moderate Minimal Moderate




Dose adjustment Yes Not usual Yes
Cost/month $5–20 $60–100 $10–30
OCD, obsessive-compulsive disorder.
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IBS,183 and paroxetine, because of its greater anticholin-
ergic effect, may be selected for patients with diarrhea.
In addition, there are other, novel antidepressants,
such as mirtazapine, which has the potentially beneficial
5-HT3 receptor blocking effect and is particularly indi-
cated in the patient with poor sleep and inability to gain
weight. Venlaxafine produces combined serotonin and
norepinephrine uptake inhibition and has been shown to
increase stimulated pain thresholds216; it has been sug-
gested for treatment of certain chronic painful disor-
ders.217
Anxiolytic medications (benzodiazepines or azapi-
rones) have sometimes been prescribed for patients with
IBS because of the frequent comorbidity of anxiety dis-
orders with IBS218 and many recognize that acute psy-
chological distress can make bowel symptoms worse.
Two small studies support the efficacy of benzodiazepines
for IBS,219,220 but the drug-placebo difference was rela-
tively small. In view of weak treatment effects and a
potential for physical dependence and interaction with
other drugs, caution should be used when prescribing
benzodiazepine anxiolytics, and when prescribed, it
should be for a self-limited period of 1–3 weeks. More
recently, there is preliminary evidence suggesting that
5-HT1 agonists like buspirone may have a role in de-
creasing GI symptoms because of their effects on relaxing
visceral organs.181,221 However, it is not clear if central or
peripheral effects mediate the therapeutic effects in IBS,
and further studies are needed to confirm these initial
impressions.
It is important to communicate the value of centrally
acting drugs in treating symptoms of IBS within the
context of an effective physician-patient relationship.
Several guidelines are recommended.100,153
Address patient perceptions and expectations for
taking antidepressants. Some patients may refuse to
take an antidepressant or may be noncompliant222 be-
cause they perceive: (1) that they are being treated for a
psychiatric problem, (2) that the medication may be
addicting or “mind altering,” or (3) they do not think the
doctor accepts the symptoms as “real.” These issues need
to be properly addressed and clarified when they occur.
Provide a rationale for medication use that is
consistent with the patient’s expectations. The patient
can be informed that for IBS, antidepressants act as
central analgesics that work sooner, and in lower dosages,
than when they are used to treat major depression.223 The
medication reduces visceral afferent activity directly or
by facilitating descending inhibitory pathways that con-
trol pain; however, it can also help to treat depressive
symptoms induced by the illness.153
Negotiate a treatment plan. The choice of a par-
ticular drug is based on: (1) the target symptoms to be
treated, (2) the medication’s side effect profile, (3) cost,
and (4) the patient’s previous experiences and prefer-
ences. The patient should be involved in making the
selection of a particular medication. The patient should
also be informed that benefit may occur no sooner than
3–4 weeks (although benefit can occur sooner), and that
side effects, if they occur, tend to diminish in 1–2 weeks.
TCAs start with lower dosages (e.g., 25–50 mg) and
work up to full therapeutic (150 mg) dosages over several
weeks. With SSRIs, only one pill is all that is usually
required. Treatment is continued for 6–12 months be-
fore tapering, and dosage adjustments are usually mutu-
ally determined.
Continue phone contact with the patient to as-
sess compliance and side effects. Because the benefit of
the medication will not occur for several weeks, and
because side effects occur immediately, it helps to have
an initial phone contact with the patient during the first
week of treatment (and possibly repeat the phone call
2–3 weeks later). This is done to make decisions about
possible dose or medication changes, and if needed, to
help motivate the patient to continue the medication.
The response to the treatment is not based only on
symptom reduction, but also by improvement in daily
function, quality of life, and emotional state. If side
effects occur, it is best to hold the same dosage or reduce
it, and only if required, to switch to another medication
(preferably within the same class).224
Consider alternates if treatment response is sub-
optimal. When symptoms are refractory, switching to a
different class of antidepressant may be considered. Oc-
casionally, a low-dose TCA can be combined with an
SSRI213; there is evidence to suggest an augmenting
effect of combining psychological treatment with an
antidepressant.211
Conclusions
There is sufficient evidence to conclude that IBS is
an important medical disorder with significant impact on
those afflicted with regard to symptom severity, disabil-
ity, and impaired quality of life. Furthermore, the bur-
den to society in terms of direct health care costs and
indirect effects including work absenteeism exceeds that
of most GI disorders. The authors believe that a com-
pelling need exists for investigations that address the
mechanisms for these effects through basic studies, as
well as pharmacological and behavioral treatment trials
to help ameliorate the suffering of patients so afflicted.
Meanwhile, there is some empiric evidence for a diag-
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nostic and hierarchical treatment approach based on pre-
dominant symptom type, its severity, and associated
clinical and psychosocial features.
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217. Pernia A, Micó JA, Calderón E, Torres LM. Venlafaxine for the
treatment of neuropathic pain. J Pain Symptom Manage 2000;
19:408–410.
218. Lydiard RB, Falsetti SA. Experience with anxiety and depression
treatment studies: implications for designing irritable bowel
syndrome clinical trials. Am J Med 1999;107:65S–73S.
219. Ritchie JA, Truelove SC. Comparison of various treatments for
irritable bowel syndrome. BMJ 1980;281:1317–1319.
220. Baume P, Cuthbert J. The effect of medazepam in relieving
symptoms of functional gastrointestinal distress. Aust N Z
J Med 1973;3:457–460.
221. Tack J, Piessevaux H, Coulie B, Caenepeel P, Janssens J. Role
of impaired gastric accommodation to a meal in functional
dyspepsia. Gastroenterology 1998;115:1346–1352.
222. Cakkues AL, Popkin MK. Antidepressant treatment of medical-
surgical inpatients by nonpsychiatric physicians. Arch Gen Psy-
chiatry 1987;44:157–160.
223. Clouse RE, Lustman P, Geisman RA. Antidepressant therapy in
138 patients with irritable bowel syndrome: a five-year clinical
experience. Aliment Pharmacol Ther 1994;8:409–416.
224. Brown WA, Harrison W. Are patients who are intolerant to one
December 2002 AMERICAN GASTROENTEROLOGICAL ASSOCIATION 2129
serotonin selective reuptake inhibitor intolerant to another?
J Clin Psychiatry 1995;56:30–34.
225. Jones R, Lydeard S. Irritable bowel syndrome in the general
population. BMJ 1992;304:87–90.
226. Zuckerman MJ, Guerra LG, Drossman DA, Foland JA, Gregory
GG. Comparison of bowel patterns in Hispanics and non-His-
panic whites. Dig Dis Sci 1995;40:1761–1769.
227. Taub E, Cuevas JL, Cook EW, Crowell M, Whitehead WE. Irritable
bowel syndrome defined by factor analysis: gender and race
comparisons. Dig Dis Sci 1995;40:2647–2655.
228. Osterberg E, Blomquist L, Krakau I, Weinryb RM, Asberg M,
Hultcrantz R. A population study on irritable bowel syndrome
and mental health. Scand J Gastroenterol 2000;35:264–268.
229. Boyce PM, Koloski NA, Talley NJ. Irritable bowel syndrome
according to varying diagnostic criteria: are the new Rome II
criteria unnecessarily restrictive for research and practice? Am J
Gastroenterology 2000;95:3176–3182.
230. Talley NJ, Howell S, Poulton R. The irritable bowel syndrome and
psychiatric disorders in the community: is there a link? Am J
Gastroenterol 2001;96:1072–1079.
231. Thompson WG, Irvine EJ, Pare P, Ferrazzi S, Rance L. Functional
gastrointestinal disorders in Canada: first population based
survey using Rome II criteria with suggestions for improving the
questionnaire. Dig Dis Sci 2002;47:225–235.
232. Van Wijk HJ, Smout AJPM, Akkermans LMA, Roelofs JMM, ten
Thije OJ. Gastric emptying and dyspeptic symptoms in the irri-
table bowel syndrome. Scand J Gastroenterol 1992;27:99–
102.
233. Evans PR, Bak YT, Shuter B, Hoschl R, Kellow JE. Gastroparesis
and small bowel dysmotility in irritable bowel syndrome. Dig Dis
Sci 1997;42:2087–2093.
234. Caballero-Plasencia AM, Valenzuela-Barranco M, Herrerias-Gu-
tierez JM, Esteban-Carretero JM. Altered gastric emptying in
patients with irritable bowel syndrome. Eur J Nucl Med 1999;
26:404–409.
235. Welgan P, Meshkinpour H, Ma J. Role of anger in antral motor
activity in irritable bowel syndrome. Dig Dis Sci 2000;45:248–
251.
236. Leahy A, Besherdas K, Clayman C, Mason I, Epstein O. Abnor-
malities of the electrogastrogram in functional gastrointestinal
disorders. Am J Gastoenterol 1999;94:1023–1028.
237. Kumar D, Wingate DL. The irritable bowel syndrome: a paraxys-
mal motor disorder. Lancet 1985;2:973–977.
238. Kellow JE, Gill RC, Wingate DL. Prolonged ambulant recordings
of small bowel motility demonstrate abnormalities in the irrita-
ble bowel syndrome. Gastroenterology 1990;98:1208–1218.
239. Schmidt T, Hackelsberger N, Widmer R, Meisel C, Pfeiffer A,
Kaess H. Ambulatory 24-hour jejunal motility in diarrhea-pre-
dominant irritable bowel syndrome. Scand J Gastroenterol
1996;31:581–589.
240. Simren M, Castedal M, Svedlund J, Abrahamsson H, Bjornsson
E. Abnormal propagation pattern of duodenal pressure waves in
the irritable bowel syndrome (IBS). Dig Dis Sci 2000;45:2151–
2161.
241. Gorard DA, Libby GW, Farthing MJG. Ambulatory small intestinal
motility in ‘diarrhoea’ predominant irritable bowel syndrome.
Gut 1994;35:203–210.
242. Fukudo S, Nomura T, Hongo M. Impact of corticotropin-releasing
hormone on gastrointestinal motility and adrenocorticotropic
hormone in normal controls and patients with irritable bowel
syndrome. Gut 1998;42:845–849.
243. Kellow JE, Phillips SF. Altered small bowel motility in irritable
bowel syndrome is correlated with symptoms. Gastroenterology
1987;92:1885–1893.
244. Kellow JE, Langeluddecke PM, Eckersley GM, Jones MP, Ten-
nant CC. Effects of acute psychologic stress on small-intestinal
motility in health and the irritable bowel syndrome. Scand J
Gastroenterol 1992;27:53–58.
245. Cann PA, Read NW, Brown C, Hobson N, Holdsworth CG. Irrita-
ble bowel syndrome: relationship of disorders in the transit of a
single solid meal to symptom patterns. Gut 1983;24:405–411.
246. Lu CL, Chen CY, Chang FY, Lee SD. Characteristics of small
bowel motility in patients with irritable bowel syndrome and
normal humans: an Oriental study. Chinese Science 1998;95:
165–169.
247. Vassallo MJ, Camilleri M, Phillips SF, Steadman CJ, Talley NJ,
Hanson RB, Haddad AC. Colonic tone and motility in patients
with irritable bowel syndrome. Mayo Clin Proc 1992;67:725–
731.
248. Whitehead WE, Drescher VM. Perception of gastric contractions
and self-control of gastric motility. Psychophysiology 1980;17:
552–558.
249. Rogers J, Henry MM, Misiewicz JJ. Increased segmental activity
and intraluminal pressures in the sigmoid colon of patients with
the irritable bowel syndrome. Gut 1989;30:634–641.
250. Fukudo S, Suzuki J. Colonic motility, autonomic function, and
gastrointestinal hormones under psychological stress on IBS.
Tohoku J Exp Med 1987;151:373–385.
251. Ladabaum U, Minoshima S, Hasler WL, Cross D, Chey WD,
Owyang C. Gastric distention correlated with activation of mul-
tiple cortical and subcortical regions. Gastroenterology 2001;
120:369–376.
252. Bueno L, Fioramonti J, Ruckebusch Y, Frexinos J, Coulom P.
Evaluation of colonic myoelectrical activity in health and func-
tional disorders. Gut 1980;21:480–485.
253. Vassallo M, Camilleri M, Phillips SF, Brown ML, Chapman NJ,
Thomforde GM. Transit through the proximal colon influences
stool weight in the irritable bowel syndrome. Gastroenterology
1992;102:102–108.
254. Whitehead WE, Crowell MD, Davidoff AL, Palsson OS, Schuster
MM. Pain from rectal distension in women with irritable bowel
syndrome: relationship to sexual abuse. Dig Dis Sci 1997;42:
796–804.
255. Blomhoff S, Jacobsen MB, Spetalen S, Vatn M, Malt UF. Rectal
tone and brain information processing in irritable bowel syn-
drome. Dig Dis Sci 2000;45:1153–1159.
256. Horikawa Y, Mieno H, Inoue M, Kajiyama G. Gastrointestinal
motility in patients with irritable bowel syndrome studied by
using radiopaque markers. Scand J Gastroenterol 1999;34:
1190–1195.
257. MacDonald AJ, Bouchier IAD. Non-organic gastrointestinal ill-
ness: a medical and psychiatric study. Br J Psychiatry 1980;
136:276–283.
258. Craig TKJ, Brown GW. Goal frustration and life events in the
aetiology of painful gastrointestinal disorder. J Psychosom Res
1984;28:411–421.
259. Colgan S, Creed FH, Klass SH. Psychiatric disorder and abnor-
mal illness behaviour in patients with upper abdominal pain.
Psychol Med 1988;18:887–892.
260. Corney RH, Stanton R. Physical symptom severity, psychologi-
cal and social dysfunction in a series of outpatients with irrita-
ble bowel syndrome. J Psychosom Res 1990;34:483–491.
261. Toner BB, Garfinkel PE, Jeejeebhoy KN. Psychological factors in
irritable bowel syndrome. Can J Psychiatry 1990;35:158–161.
262. Blanchard EB, Scharff L, Schwartz SP, Suls JM, Barlow DH. The
role of anxiety and depression in the irritable bowel syndrome.
Behav Res Ther 1990;28:401–405.
263. Walker EA, Gelfand AN, Gelfand MD, Katon WJ. Psychiatric
diagnoses, sexual and physical victimization, and disability in
patients with irritable bowel syndrome or inflammatory bowel
disease. Psychol Med 1995;25:1259–1267.
264. Irwin C, Falsetti SA, Lydiard RB, Ballenger JC, Brock CD, Brener
2130 AMERICAN GASTROENTEROLOGICAL ASSOCIATION GASTROENTEROLOGY Vol. 123, No. 6
W. Comorbidity of posttraumatic stress disorder and irritable
bowel syndrome. J Clin Psychiatry 1996;57:576–578.
265. Drossman DA. Review article: an integrated approach to the
irritable bowel syndrome. Aliment Pharmacol Ther 1999;
13(suppl 2):3–14.
266. Svedlund J. Psychotherapy in irritable bowel syndrome: a con-
trolled outcome study. Acta Psychiatr Scand 1983;67;(suppl
306):1–86.
267. Creed FH, Fernandes L, Guthrie E, Palmer S, Ratcliffe J, Read N,
Rigby C, Thompson DG, Tomenson B. The cost-effectiveness of
psychotherapy and SSRI antidepressants for severe irritable
bowel syndrome (abstr). Gastroenterology 2001;120:A115.
268. Bennett P, Wilkinson S. A comparison of psychological and
medical treatment of the irritable bowel syndrome. Br J Clin
Psychol 1985;24:215–216.
269. Greene B, Blanchard EB. Cognitive therapy for irritable bowel
syndrome. J Consult Clin Psychol 1994;62:576–582.
270. van Dulmen AM, Fennis JFM, Bleijenberg G. Cognitive-behav-
ioral group therapy for irritable bowel syndrome: effects and
long-term follow-up. Psychosom Med 1996;58:508–514.
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